Phathom Pharmaceuticals annual net income
2018
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Net Income Growth & History (PHAT)
Phathom Pharmaceuticals's net income was −$221.2M for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$221.2M | $113.1M | — |
| 2024 | 2024-12-31 | −$334.3M | −$132.7M | — |
| 2023 | 2023-12-31 | −$201.6M | −$3.9M | — |
| 2022 | 2022-12-31 | −$197.7M | −$53.8M | — |
| 2021 | 2021-12-31 | −$143.9M | −$14.8M | — |
| 2020 | 2020-12-31 | −$129.1M | $126.1M | — |
| 2019 | 2019-12-31 | −$255.1M | −$253.8M | — |
| 2018 | 2018-12-31 | −$1.3M | — | — |
Phathom Pharmaceuticals quarterly net income
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$17.6M | $58.2M | — |
| Q1 2026 | 2026-03-31 | −$30.4M | $63.9M | — |
| Q4 2025 | 2025-12-31 | −$21.1M | $53.3M | — |
| Q3 2025 | 2025-09-30 | −$30.0M | $55.6M | — |
| Q2 2025 | 2025-06-30 | −$75.8M | $15.6M | — |
| Q1 2025 | 2025-03-31 | −$94.3M | −$11.5M | — |
| Q4 2024 | 2024-12-31 | −$74.5M | $5.1M | — |
| Q3 2024 | 2024-09-30 | −$85.6M | −$42.3M | — |
| Q2 2024 | 2024-06-30 | −$91.4M | −$50.5M | — |
| Q1 2024 | 2024-03-31 | −$82.9M | −$45.0M | — |
| Q4 2023 | 2023-12-31 | −$79.6M | −$24.5M | — |
| Q3 2023 | 2023-09-30 | −$43.2M | $7.8M | — |
| Q2 2023 | 2023-06-30 | −$41.0M | $10.0M | — |
| Q1 2023 | 2023-03-31 | −$37.8M | $2.9M | — |
| Q4 2022 | 2022-12-31 | −$55.0M | −$19.2M | — |
| Q3 2022 | 2022-09-30 | −$51.1M | −$14.4M | — |
| Q2 2022 | 2022-06-30 | −$50.9M | −$14.4M | — |
| Q1 2022 | 2022-03-31 | −$40.7M | −$5.8M | — |
| Q4 2021 | 2021-12-31 | −$35.8M | $17.9M | — |
| Q3 2021 | 2021-09-30 | −$36.7M | −$2.6M | — |
| Q2 2021 | 2021-06-30 | −$36.6M | −$15.5M | — |
| Q1 2021 | 2021-03-31 | −$34.8M | −$14.7M | — |
| Q4 2020 | 2020-12-31 | −$53.7M | $44.3M | — |
| Q3 2020 | 2020-09-30 | −$34.1M | $34.0M | — |
| Q2 2020 | 2020-06-30 | −$21.1M | $66.7M | — |
| Q1 2020 | 2020-03-31 | −$20.1M | −$18.9M | — |
| Q4 2019 | 2019-12-31 | −$98.0M | −$97.5M | — |
| Q3 2019 | 2019-09-30 | −$68.1M | −$67.8M | — |
| Q2 2019 | 2019-06-30 | −$87.8M | −$87.5M | — |
| Q1 2019 | 2019-03-31 | −$1.3M | −$997,000 | — |
| Q4 2018 | 2018-12-31 | −$484,000 | — | — |
| Q3 2018 | 2018-09-30 | −$290,000 | — | — |
| Q2 2018 | 2018-06-30 | −$260,000 | — | — |
| Q1 2018 | 2018-03-31 | −$254,000 | — | — |
Phathom Pharmaceuticals net income trends
Over the last five fiscal years, Phathom Pharmaceuticals's net income decreased from −$129.1M to −$221.2M, a change of −$92.2M. The latest reported quarter, Q2 2026, shows −$17.6M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
